Novel quinoxaline-3-propanamides as VGFR-2 inhibitors and apoptosis inducers.

ABSTRACT: Vascular endothelial growth factor receptor-2 is a vital target for therapeutic mediation in various types of cancer. This study was aimed at exploring the cytotoxic activity of seventeen novel quinoxaline-3-propanamides against colon cancer (HCT-116) and breast cancer (MCF-7) using MTT assay. Results revealed that compounds 8, 9, and 14 elicited higher cytotoxicity than the reference drugs, doxorubicin (DOX) and sorafenib. Interestingly, they are more selective for HCT-116 (SI 11.98-19.97) and MCF-7 (SI 12.44-23.87) compared to DOX (SI HCT-116 0.72 and MCF-7 0.9). These compounds effectively reduced vascular endothelial growth factor receptor-2; among them, compound 14 displayed similar VEGFR-2 inhibitory activity to sorafenib (IC₅₀ 0.076 M). The ability of 14 to inhibit angiog

SUBMITTER: Ismail MMF 

PROVIDER: S-EPMC10616755 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature